Aix-Marseille Université, IRD, AP-HM, MEPHI, IHU-Méditerranée Infection, Marseille, France.
Aix-Marseille Université, IRD, AP-HM, MEPHI, IHU-Méditerranée Infection, Marseille, France.
Int J Antimicrob Agents. 2019 Apr;53(4):371-382. doi: 10.1016/j.ijantimicag.2018.11.010. Epub 2018 Nov 23.
Antimicrobial resistance is considered a major public-health issue. Policies recommended by the World Health Organization (WHO) include research on new antibiotics. No new class has been discovered since daptomycin and linezolid in the 1980s, and only optimisation or combination of already known compounds has been recently commercialised. Antibiotics are natural products of soil-living organisms. Actinobacteria and fungi are the source of approximately two-thirds of the antimicrobial agents currently used in human medicine; they were mainly discovered during the golden age of antibiotic discovery. This era declined after the 1970s owing to the difficulty of cultivating fastidious bacterial species under laboratory conditions. Various strategies, such as rational drug design, to date have not led to the discovery of new antimicrobial agents. However, new promising approaches, e.g. genome mining or CRISPR-Cas9, are now being developed. The recent rebirth of culture methods from complex samples has, as a matter of fact, permitted the discovery of teixobactin from a new species isolated from soil. Recently, many biosynthetic gene clusters were identified from human-associated microbiota, especially from the gut and oral cavity. For example, the antimicrobial lugdunin was recently discovered in the oral cavity. The repertoire of human gut microbiota has recently substantially increased, with the discovery of hundreds of new species. Exploration of the repertoire of prokaryotes associated with humans using genome mining or newer culture approaches could be promising strategies for discovering new classes of antibiotics.
抗微生物药物耐药性被认为是一个主要的公共卫生问题。世界卫生组织(世卫组织)推荐的政策包括研究新的抗生素。自 20 世纪 80 年代的达托霉素和利奈唑胺以来,尚未发现新的抗生素类别,最近仅对已有的化合物进行了优化或组合。抗生素是土壤生物自然产生的产物。放线菌和真菌是目前用于人类医学的大约三分之二抗菌剂的来源;它们主要是在抗生素发现的黄金时代发现的。自 20 世纪 70 年代以来,由于难以在实验室条件下培养挑剔的细菌物种,这一时代已经衰落。到目前为止,各种策略,如合理药物设计,并没有导致新的抗菌剂的发现。然而,新的有前途的方法,例如基因组挖掘或 CRISPR-Cas9,现在正在开发中。事实上,从复杂样本中复活的培养方法最近已经允许从土壤中分离的新物种中发现泰妙菌素。最近,许多生物合成基因簇已从与人类相关的微生物群,特别是从肠道和口腔中被鉴定出来。例如,最近在口腔中发现了抗菌剂 lugdunin。人类肠道微生物群的 repertoire 最近有了很大的增加,发现了数百种新物种。使用基因组挖掘或更新的培养方法探索与人类相关的原核生物的 repertoire 可能是发现新类抗生素的有前途的策略。